---
tags:
  - cancer
aliases:
  - tamoxifen
  - raloxifene
---
# COCP & Cancer risk
>[!warning]
>COCP increases risk for Breast & Cervix cancer, Fibroid, Cervical ectropion.

>[!info]
>COCP decreases risk for Endometrial & Ovarian, Colorectal cancer.

([Sync](onenote:#OBG&section-id={210C3954-BE8B-A24C-8E7F-F1B991349700}&page-id={C0BF59D1-BCE5-4374-B171-1903D87D88C1}&object-id={770EDEF0-7B2F-4A90-8313-D45C65FEB45E}&7C&base-path=https://d.docs.live.net/450c0e1b0b9c7922/Documents/Onenote/MBBS/PLAB%201%20+%20MSRA.one))

# Drugs used in gynae cancers
## Tamoxifen
- Anti-Estrogenic action on: Breast (reduces ER+ve tumor size), Peripheral sites (hot flushes)
- Estrogenic action on: Endometrium (proliferation), Bone (Anti-resorptive), Plasma lipid (reduces Chl), Blood (VTE)

## Raloxifene
- Anti-Estrogenic action on: Breast (reduces tumor size), Endometrium (No proliferation)
- Estrogenic action on: Bone (Anti-resorptive), Plasma lipid (reduces Chl), Blood (Increase VTE)

## Summary
Both reduce Breast cancer, protect bone, keep lipid low,
Both increase risk of VTE.
Tamoxifen causes Endometrial Ca, Raloxifene doesn't.